The expression of CYP2W1 in ACC makes this enzyme a promising drug target, by taking advantage of its ability to convert nontoxic prodrugs (i.e. duocarmicyn precursors) into highly potent tumor toxins. This evidence concerns the gene CYP2W1 and neoplasm.